Clinical Trial Search

Phase 3 N=362 One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension

Hypertension

Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events From Day 1 Through End of the Study - Cohort 1. — 267; 73.8 participants

Takeda Results Apr 2011 7.8% serious AE View details

Phase 3 N=516 Reverse Shoulder Prosthesis Study

Rotator Cuff Arthropathy · Failed Total Shoulder · Failed Hemi-arthroplasty

Primary: American Shoulder and Elbow Surgeons Shoulder Score — 76; 62; 77 Units on a scale

Encore Medical, L.P. Results Apr 2011 0.0% serious AE View details

Phase 3 N=345 A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-label Extension Study

Diabetic Macular Edema

Primary: Core Study: Difference Between the Baseline Level of Visual Acuity (Letters) of the Study Eye and the Mean Visual Acuity Averaged Over All Monthly Post-baseline…

Novartis Results Apr 2011 34.5% serious AE View details

Phase 3 N=566 Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension

Hypertension

Primary: Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. — -24.79; -24.51; -13.60 mmHg — p=<0.001

Takeda Results Apr 2011 0.7% serious AE View details

Phase 3 N=885 Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension

Hypertension

Primary: Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure. — -20.63; -21.24; -12.22 mmHg — p=<.001

Takeda Results Apr 2011 2.9% serious AE View details

Phase 3 N=1,075 Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%

Acne Vulgaris

Primary: Co-Primary Endpoint: Success Rate on Investigator's Global Assessment (IGA) From Baseline to Week 12 — 26.3; 17.3 Percentage of Participants

Galderma R&D Results Apr 2011 0.4% serious AE View details

Phase 3 N=415 Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential Hypertension

Hypertension

Primary: Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. — -7.70; -10.48; -2.70 mmHg — p=0.001

Takeda Results Apr 2011 1.0% serious AE View details

Phase 3 N=321 Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization

Macular Degeneration · Choroidal Neovascularization

Primary: Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) of the Study Eye at Month 12 — 53.7; 54.6; 54.8; 59.0 Letters

Novartis Results Apr 2011 31.8% serious AE View details

Phase 3 N=526 Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail

Onychomycosis

Primary: Efficacy Assessed by the Percentage of Participants With Complete Cure at the End of Study (Week 52) After Treating for 24 or 48 Weeks — 1.50; 0.77; 2.96; 0 Percentage…

Novartis Pharmaceuticals Results Apr 2011 5.2% serious AE View details

Phase 3 N=984 Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension

Hypertension

Primary: Change From Baseline in 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. — -14.93; -15.32; -11.29 mmHg — p=<0.001

Takeda Results Apr 2011 2.2% serious AE View details

Phase 3 N=30 Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS), in Adult Renal Transplant Patients in Maintenance.

Renal Transplantation

Primary: Change in Glomerular Filtration Rate Estimated by Iohexol Plasma Clearance 12 Months After Randomization Between the 2 Groups of Patients. — -4.07; 10.30 (mL/min)

Novartis Pharmaceuticals Results Apr 2011 60.0% serious AE View details

Phase 3 N=419 Mobile - Bearing Knee Study

Inflammatory Tissue Disorder · Osteoarthritis · Avascular Necrosis

Primary: Knee Society Score Evaluation — 93.1 Average Knee Rating Score

Encore Medical, L.P. Results Apr 2011 0.0% serious AE View details

Phase 3 N=1,291 An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.

Hypertension

Primary: Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. — -13.42; -14.53; -10.22; -11.99 mmHg — p=<0.001

Takeda Results Apr 2011 1.1% serious AE View details

Phase 3 N=1,066 Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%

Acne Vulgaris

Primary: Co-Primary Endpoint: Success Rate on Investigator's Global Assessment (IGA) From Baseline to Week 12 — 24.1; 16.4 Percentage of Participants

Galderma R&D Results Apr 2011 0.0% serious AE View details

Phase 3 N=285 Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients

Transplantation Infection

Primary: Number of Participants With Biopsy-proven Acute Rejection — 21; 21 Participants

Novartis Pharmaceuticals Results Apr 2011 61.4% serious AE View details